National Health (Pharmaceutical Benefits Therapeutic Groups) Amendment Determination 2016 (No. 1) (PB 24 of 2016) (Cth)

PB 24 of 2016

National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2016 (No. 1)

National Health Act 1953

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 84AG(1) of the National Health Act 1953.

Dated        30       March 2016

ADRIANA PLATONA

Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2016 (No. 1).

(2)     This Determination may also be cited as PB 24 of 2016.

1. Commencement

   This Determination commences on 1 April 2016.

3              Amendments to PB 1 of 2010

Schedule 1 amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 (PB 1 of 2010).

Schedule 1             Amendments

[1]      Section 4 Definitions

omit:

PPI group means the Proton pump inhibitor group.

Venlafaxine group means the Venlafaxine and Venlafaxine derivative antidepressants group.

[2]      Omit entry for Schedule 1, Part 5 and Part 8